DAne Dickson, MD, founder and CEO of Taproot Health - Episode 18
There’s no question that we are awash in promising new technologies with the potential to advance precision medicine. But is the existing infrastructure adequate to bring innovation into patient care? It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial. These trials, however, are extremely costly and time-consuming and generate only limited conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience. Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward? Dane Dixon, MD, of Taproot Health joins us in one of our most important episodes to date.